Method of treating breast cancer
SUBSTANCE: invention refers to medicine, particularly to oncology, and may be applied in treating breast cancer. Breast is resected. Coletex-Mex textile tissue is applied for 4-7 days in 7-10 postoperative days on the postoperative scar and remained breast tissues, and changed 2 times a day. For the following 4-7 days, Coletex-D hydrogel tissue is applied and coated with Coletex-SMT textile tissue in the same regiment. The applications for 8-10 hours a day are combined with radiation teletherapy to SRD 20 Gy - 25 Gy. The radiation teletherapy is combined with the applications of Coletex gel DNA hydrogel coated with Coletex-Mex textile tissues from above changed twice a day. The radiation teletherapy is followed by the application of Coletex-SMT tissue and Coletex-Mex tissues changed every 12 hours to complete rehabilitation.
EFFECT: method provides fast healing of the postoperative wound, reduced length of the beginning of radiation and chemotherapy, minimal rate of complications and side reactions thereby improving patient's quality of life.
The invention relates to medicine, namely to Oncology.
There is a method of treatment of infiltrative edematous breast cancer (Patent RF №2177349, IPC A61N 5/00, publ. 2001), including systemic and regional chemotherapy with embolization of the arteries supplying the tumor, and subsequent application of radiation therapy immediately after chemoembolization. Chemoradiation treatment on the background of the introduction of patient prednisone. Radiation therapy is carried out in a mode of secondary fractionation doses up to 3 G 5 times a week to a total dose of 45 Gy to the base of the breast and up to 33-36 Gr zone of regional lymph flow.
The disadvantage of this method is that when conducting this treatment, possible complications, due to the high risk of thrombosis. To conduct regional chemotherapy requires special equipment and trained personnel.
There is a method of treatment of advanced breast cancer with tumor ulceration of the skin (Patent RF №2176922, IPC A61N 5/00, publ. 2001), including chemotherapy 5-fluorouracil in the form of napkins "Collex-5-ftor"imposed on the region of the tumor every day 2-3 times a day, and radiation therapy to the area of the base of the breast and the area of regional lymphatic drainage. Additionally, daily entered the prednisolone 20-30 mg orally or 30 mg intramuscularly, radiation therapy was performed on the background of the action of these drugs daily for 3 Gr per day to the total focal dose of SOD 45 Gy on the basis of breast cancer and to SOD 33-36 Gr zone of regional lymph flow, after radiation therapy, the dose of prednisolone every 2-3 days was reduced by 5-10 mg, napkins "Collex-5-ftor" is replaced with "Collex-CHG" or "Collex-D" and used them to complete scarring, and 2-3 weeks after radiotherapy was performed traditional chemotherapeutic treatment.
The disadvantage of this method is the need for long-term use of prednisolone, which can have serious side effects such as gastro-intestinal tract or to be an absolute contraindication to its use in the presence of peptic ulcer or erosive gastritis patient.
The closest is a method of treating breast cancer (Patent RF №2349264, IPC AV 17/00, publ. 2009), which includes resection of breast cancer and radiation therapy to the tumor bed after surgery. 2 weeks after surgery undergo chemotherapy and 2-4 weeks for standard mode fractionation dose, do remote gamma-therapy.
The disadvantage of this method of treatment is an inadequate amount of ongoing chemotherapy treatment (1st course of chemotherapy is not enough). Respectively between courses the further chemotherapeutic treatment occurs long break of up to two months or more, that significantly reduces the effectiveness of chemotherapy treatment. The next disadvantage is the inability to comply with the terms of the treatment in the presence of residual expressed surgical inflammation, not to start a course of radiation therapy. Then the timing between courses of chemotherapy treatment more elongate.
The task of the invention is to remedy these disadvantages, the efficiency of treatment, reduction of terms of rehabilitation of patients after surgical treatment and, as a consequence, adherence to deadlines beginning of the postoperative course of radiation therapy, prevention and reduction of severity of radiation reactions in the treatment process, as well as reducing recovery time after treatment. This allows you to observe the timing of the further stages of the planned treatment.
For this purpose, the method of treating breast cancer, including resection of breast cancer and radiation therapy after surgery for 7-10 day post-surgical scar and the remaining breast tissue to hold within 4-7 days of the application wipes "Collex-Mex on a textile backing with change it 2 times a day. In the next 4-7 days should be application hydrogel napkins "Collex-D"to the Yu top covered with a cloth textile based "Collex-SMC" in the same mode. Then simultaneously with the holding of sessions of remote radiation therapy to SOD 20-25 Gy to continue this application mode 8-10 hours a day. Next, simultaneously with the continuation of remote radiation therapy proposed to carry out the application of the hydrogel material "Collex-gel-DNA, which are covered with cloth textile based "Collex-Mex with change 2 times per day. After completion of the course of radiation remote therapy recommended application napkins "Collex-SMC and Collex-Mex, alternating every 12 hours up to full rehabilitation.
The proposed method allows for more quickly to stop post-operative swelling of the tissues, helps in the healing of postoperative wounds and reduce the time before the start of radiation therapy, as well as to undertake a course of radiation therapy without interruption due to a decrease in the intensity of radiation reactions and accelerate the rehabilitation of the patient. In this regard, reduced time to initiation of chemotherapy. Sharing hydrogel and textile napkins improves the mass transfer of the drug into the damaged tissue to achieve joint action of drugs and possible traumas of appliciable, use a moistened textile and hydrogel applications reduces soreness dressings, making them the safest. All this pozvolyayushchii outcomes and quality of life.
The method is as follows.
Patients diagnosed with breast cancer in most cases shows segmental or complete resection of the breast. After the initial scarring 7-10 days after surgery postoperative scar and the remaining breast tissue causing the tissue "Collex-Mex with Mexidol on a textile backing with change it 2 times a day for 4-7 days.
5-8 days start to apply hydrogel napkin "Collex-D" with Dimexidum, which are covered with cloth textile based "Collex-SMC" with urea for 4-7 days with change 2 times per day.
On 8-14 day begin postoperative course of radiation therapy to the remaining breast tissue in mode unconventional fractionation with GENUS - 2,5 Gr. During radiation treatment, daily continue to use the same application (napkin "Collex-D" with Dimexidum, which are covered with cloth textile based "Collex-SMC" with urea) mode 8-10 hours a day to take stock of 20 Gy To 25 Gy.
Remote radiation therapy continue with the RACE - 2,5 Gr and SOD - 50 Grams or SOD - 45 Gr and then boost on the fabric postoperative scar GENUS - 2,8 Gr 3 session energy of the electron beam of 4 MeV to SOD - 53,4 Gr. At the same time hold the applique material hydro is spruce "Collex-gel-DNA", which are covered with cloth textile based "Collex-Mex with change 2 times per day. This allows you to stop radiation reaction and undergo irradiation without interruption.
After completion of the course of radiation treatment applications napkins "Collex-SMC and napkins "Collex-Mex, alternating every 12 hours up to full rehabilitation.
Clinical diagnosis: Cancer of the right mammary gland II And Art., T2N0M0. Condition during multimodality treatment (surgery: radical resection of the right breast with the plastic fragment latissimus from, 13.04.11).
The 1st stage of the operation: radical resection of the right breast with the plastic fragment latissimus from 13.04.11,
In the second stage the recommended postoperative radiation therapy to the remaining tissue of the right breast with subsequent courses of polychemotherapy according to the scheme CAF.
Clinically admission: large Breasts, the 5th dimension bra. Postoperative scar breast swollen right, the sutures were removed after one in the outer quadrants of the breast rocky density, sedentary, with multiple subcutaneous hemorrhages. The scar multiple brown.
The patient is scheduled on day 8 after surgery applications with cloth Collex-Mex on textile the basis change it 2 times a day, during the day napkins were specialise according to the instructions. The treatment was carried out for 7 days. On the 5th day of applications was made by predlozena 3D SKT markup breast cancer. After 7 days expressed positive dynamics in the form of a resolution subcutaneous hemorrhages 75%complete healing of the scar, reducing edema of the mammary gland.
On the 8th day the application was continued under the scheme: hydrogel napkin "Collex-D" with Dimexidum covered with cloth textile based "Collex-SMC" with urea with change 2 times per day.
On the 12th day was initiated postoperative radiation therapy to the remaining breast tissue, the apparatus of the Terratron, gamma radiation in terms of conformal radiation, with the GENUS - 2,5 Gr and SOD - 25 Gr. While simultaneously held the same application in the exposure mode 8-10 hours per day. At the dose of 25 Gy, the patient developed poorly defined epidermic 1-St degree.
Further, since the 23 day, the irradiation was continued until the SOD 53,4 Gr. At the same time was appointed applique material hydrogel "Collex-gel-DNA, which are covered with cloth textile based "Collex-Mex with change 2 times per day.
Radiation therapy is not interrupted. In this combination the application was performed daily until the end of treatment
By the end of the irradiation of the patient revealed the development in the submammary fold wet epidermitis (II degree) (mammary glands large size).
The patient after radiation therapy were recommended applications under the scheme: napkins "Collex-SMC" with urea and napkins "Collex-Mex with Mexidol, alternating every 12 hours.
At the control examination on the 17th day full resolution wet epidermitis. All radiation areas of residual hyperpigmentation weak degree.
The rehabilitation period was 17 days.
Patient referred for further chemotherapy treatment.
In a study on the use of textile and hydrogel napkins included 32 patients with a diagnosis of breast cancer. The average age of patients was 49 years. The use of applications has allowed us: first, to reduce the period of rehabilitation in the postoperative period up to 4-5 weeks (which corresponds to the recommended timing for the start of radiation therapy in combined modality treatment plan after performing the surgical phase of treatment). Before these terms were at best 8-9 weeks. Secondly, all patients postoperative radiation therapy carried out without interruption. In addition, it significantly delay the timing of the beam d is of capabilities during treatment: the first signs of radiation reaction on the part of the skin and breast tissue developed only on SOD - 40-42,5 Gr. Earlier this dose level was 22.5-27,5 Gr.
At 31,25% (10 patients) development of radiation reactions during treatment and early postradiation period (the first 7-10 days after treatment) was not recorded.
Have to 58.1% of the patients showed development of epidermic mild degree, which was docked in 3-5 days.
The holds 18.52% of the patients showed development of radiation reactions (skin erythema moderate severity) on SOD - 40-42,5 Gy, which was maintained for 5-7 days after the treatment, during the next 3-7 days was stopped. Thus, the rehabilitation period after radiation treatment was 8-14 days. Previously, he was equal to 21-28 days.
And only 8,33% (3 patients) on the 3rd day after the end of radiation therapy showed development limited wet epidermitis in the submammary fold (with larger Breasts). The period of full rehabilitation of these patients was 17-21 day against 35-42 days without using the proposed method.
The use of textile and hydrogel napkins radiation therapy in combined modality treatment plan in patients with breast cancer is allowed to increase its effectiveness criteria the immediate and distant effects with minimal incidence of complications and adverse reactions, improving the quality of W is FDI.
A method of treating breast cancer, including resection of the mammary gland and external beam irradiation, characterized in that after the surgery 7-10 days for postoperative scar and the remaining breast tissue should be performed within 4-7 days of the application wipes "Collex-Mex on a textile backing with change it 2 times a day, in the next 4-7 days of conducting the application hydrogel napkins "Collex-D", which are covered with cloth textile based "Collex-SMC" in the same mode, and then simultaneously with the holding of sessions of remote radiation therapy to SOD 20-25gr continue this application mode for 8-10 hours a day, then simultaneously with the continuation of remote radiation treatment is the application of the hydrogel material "Collex-gel-DNA, which are covered with cloth textile based "Collex-Mex with change 2 times per day, and after a course of radiation treatment applications napkins "Collex-SMC and napkins "Collex-Mex, alternating every 12 h until full rehabilitation.
SUBSTANCE: invention refers to medicine, namely to oncology, and may be used in integrated treatment of stomach cancer. That is ensured by pre-operative blood sampling 300 ml followed by preparing autoplasma by centrifugation. All recovered autoplasma and chemopreparations are placed into a first flask; the remained blood corpuscles and chemopreparations are placed into a second flask. The flasks are separately incubated for 40 minutes at 37°C. A colonic surgery follows. The surgery begins with the drop-by-drop intravenous introduction of the incubated blood corpuscles and chemopreparations from the second flasks. Upon completion of the surgery, before closure of an abdominal wall, drain tubes are blocked; the abdominal cavity is processed with autoplasma and chemopreparations from the first flask, and autoplasma and chemopreparations are kept in the abdominal cavity. The abdominal wall is closed. Then 3 hours upon completion of the operation, the drain tubes are opened.
EFFECT: method enables reducing rate of peritoneal metastases caused by stomach cancer and increasing survival rate of the patients due to combined surgical and intraoperative intraperitoneal chemotherapy.
SUBSTANCE: invention refers to medicine, namely oncology, and may be used in integrated treatment of liver metastases of colon cancer. That is ensured by pre-operative blood sampling 200 ml followed by preparing autothrombotic mass by centrifugation. Autothrombotic mass 5 ml and chemopreparations are placed into a first flask; the remained blood corpuscles, plasma and chemopreparations are placed into a second flask. The flasks are separately incubated for 40 minutes at 37°C. A colonic laparoscopic operation follows. The operation begins with the drop-by-drop intravenous introduction of the incubated blood corpuscles and chemopreparations from the second flask. It is followed by laparoscopic extraction of liver metastases; thereafter incubated autothrombotic mass with chemopreparations from the first flask are introduced through a laparoscopic puncture needle into a bed of the extracted metastasis.
EFFECT: method enables reducing rate of tumour progression, as well as improving haemostasis within a liver resection region due to local intratissual chemotherapeutic action.
FIELD: medicine, pharmaceutics.
SUBSTANCE: what is presented is the use of a beta blocker for preparing a drug for treating hemangiomas, e.g. hemangiomas in infants. The beta blocker may represent alprenolol, bucindolol, carteolol, carvedilol, labetalol, levobunolol, medroxalol, mepindolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propafenone, propranolol, sotalol, timolol, their pharmaceutically accepted salts and mixtures.
EFFECT: what is shown is decreased proliferative activity of hemangiomas in infants under the effect of the non-selective beta-blocker propranolol, downsizing, flattening and discolouration of hemangiomas; treatment failures according to the declared invention are not found; in contrast to the use of an alternative - common corticosteroids, interferon or vincristine, usually used to treating hemangiomas; antiangiogenic action of the beta blocker in hemangiomas is shown, and the beta-2 adrenoceptor are expressed on hemangioma endotheliocytes.
19 cl, 6 dwg, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine and concerns a method of treating or modulating malignant cell population growth involving the introduction into an individual suffering a malignant tumour of an effective amount of lenalidomide, at least one corticosteroid, and at least one immunoconjugate, wherein the immunoconjugate contains at least one cell-binding agent which binds CD56, and at least one antimitotic agent wherein the cell-binding agent is an antibody, a one-chain antibody or an antigen-binding antibody fragment.
EFFECT: invention provides a therapeutic synergy or improved therapeutic index in cancer therapy as compared with separately used immunocojugate, chemotherapeutic agent used separately or in a combination with the other chemotherapeutic agent with no immunoconjugate added.
53 cl, 7 ex, 8 dwg, 7 tbl
SUBSTANCE: present group of inventions refers to medicine, namely oncology. The inventions may be used for a method of treating a tumour resistant to the VEGF antagonist therapy, as well as to a method of identifying a human individual carrying a tumour to be treated with the Bv8 antagonist. That is ensured by the effective amount of the Bv8 antagonist. The tumour is pre-treated with the vascular endothelium growth factor (VEGF) antagonist, while the Bv8 antagonist represents a Bv8 antibody or its fragment with specifying whether the individual is refractory to the VEGF antagonist therapy.
EFFECT: invention provides the effective treatment of the patients with the tumours resistant to the VEGF antagonists.
21 cl, 71 dwg, 2 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, more specifically oncology, and may be used for increasing the effectiveness of cytostatic treatment of the patients suffering malignant tumours. What is presented is the use of galactose-containing pectins prepared of sweet flag rhizomes in the integrated treatment of malignant growths.
EFFECT: possibility to increase the effectiveness of chemotherapy with the use of galactose-containing pectins is experimentally shown.
4 ex, 4 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: there are offered: an anti-cancer combination formed by VEGF Trap inhibitor with irinotecan and therapeutically applicable in treating neoplastic diseases, and a product containing it. What is shown is synergic action of the combination in growth inhibition of colonic carcinoma.
EFFECT: invention enables using the ingredients of the combination in lower doses vs those applicable separately, and increasing activity with reduced toxicity or inhibiting their manifestations.
3 cl, 1 tbl
SUBSTANCE: invention relates to compounds of formulae Ic-d , where X is O or S; R1 is selected from -(CR14R15)nNR12C(=Y)R10, -(CR14R15)nNR12S(O)2R10, -(CR14R15)nOR10, -C(=Y)NR10Rn, -C(-O)NR12(CR14R15)mNR10RH, -NHR12, C1-C12alkyl, C2-C8alkenyl, C3-C6heterocyclyl, which is a saturated carboxylic radical containing 3-6 ring atoms, wherein one ring atom is a heteroatom selected from nitrogen and oxygen, phenyl or a C4-C9heteroaryl, which is a univalent aromatic radical containing 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen and sulphur; R2 is selected from H, pyrimidinyl and C1-C6alkyl; mor is a morpholine group and R3 is a monocyclic heteroaryl group, and to pharmaceutically acceptable salts thereof.
EFFECT: compounds can be used to modulate lipid kinase activity, including PI3K, and to treat lipid kinase mediated disorders such as cancer.
15 cl, 2 tbl, 468 ex
SUBSTANCE: present invention describes substituted amides which inhibit Btk. Described are pharmaceutical compositions containing at least one of the compounds along with at least one pharmaceutically acceptable medium selected from carriers, auxiliary components and filler materials. Described are methods of treating patients suffering from several diseases which are sensitive to inhibition of activity of Btk and/or activity of B-cells. Described are methods of determining presence of Btk in a sample.
EFFECT: improved method.
58 cl, 17 ex
SUBSTANCE: invention relates to an optically active form of (-)-O-exo/C-exo-tricyclo[5.2.1.02,6]-dec-9-yl xanthic acid, having antiviral activity. The invention also relates to a pharmaceutical composition containing said compound, a method of inhibiting activity of phospholipase C, a method of treating diseases caused by a virus, such as herpes simplex virus-1, herpes simplex virus-2 or papilloma virus, for example, for treating warts, cervical dysplasia, recurrent respiratory papillomatosis, or cancer associated with papillomavirus infection, and methods of producing said compound.
EFFECT: high efficiency of using said compounds.
29 cl, 7 tbl, 11 ex
SUBSTANCE: invention refers to medicine, oncology, and may be used for treating locally advanced unresectable oesophageal cancer. Preliminary argon-plasma coagulation of a tumour is followed by high-power intraluminal brachytherapy on 1st, 8th and 15th day of the therapeutic course at single basic dose 7 Gy combined with the intravenous introduction of taxane preparations and carboplatine. Further, the tumour is exposed to tele-radiation at single basic dose 1.8 Gy, 5 fractions/week, SOD 40-45 Gy, supported by the use of fluoropyrimidine derivatives in the following doses: oral administration of capecitabine 600 mg/m2 in degree 0-1 dysphagia in days of radiation therapy, intravenous infusions of 5-fluorouracil 1000 mg/m2 in degree 2-3 dysphagia every week.
EFFECT: method provides optimising cytoreductive reaction of chemoradiation therapy components and more complete response of the tumour with relieved severe systemic and local reactions.
SUBSTANCE: invention refers to medicine, oncology, and may be used for treating the patients with stomach cancer T3-4N1-3M0. Microirrigators are inserted in an abdominal cavity during a surgical intervention. An adjuvant treatment is applied 2-3 weeks later. It involves the endolymphatic introduction of methotrexate. It is followed by a two-week gamma-therapy in accelerated fractionation mode with single radiation dose (SRD) 1.2 Gy twice a day every 5 h. Eloxatine dissolved in ozonised 5% glucose is introduced drop-by-drop in microirrigators with underlying emission on 4th, 8th and 12th day from the beginning between fractionations. In the middle of an arranged pause, the radiation therapy involves single intravenous introduction of etoposide, leucovorin, 5-fluorouracil. The second stage involves the endolymphatic introduction of methotrexate, and 2 days later gamma-therapy is applied once more in the accelerated fractionation mode with SRD 1 Gy twice a day every 5 h with underlying on 32nd, 36th and 40th day from the beginning of treatment, eloxatine dissolved in ozonised 5% glucose is introduced drop-by-drop in microirrigators between fractionations.
EFFECT: method prolongs remission, terminates process generalisation, eliminates recurrences.
2 dwg, 1 ex
SUBSTANCE: invention refers to medicine, namely paediatric surgery, and may be used for treating hemangiomas of complicated anatomical localisation. That is ensured by the intravenous bolus injection of prednisolone at 2 mg/kg of child's weight in physiologic saline 5 ml. It is followed by the intravenous introduction of cyclopohsphane at 10 mg/kg of child's weight in physiologic saline 50 ml at 50 ml/h. The therapeutic course of intravenous treatment is repeated 2 weeks later. Thereafter, the remained soft-tissue component is once exposed to close-focus roentgenotherapy in dose 1.8 to 2.5 Gy depending on a growth size.
EFFECT: method provides the effective therapy of hemangiomas of complicated anatomical localisation, reduced risk of developing potential complications, no hemangioma recurrences and en excellent cosmetic effect.
SUBSTANCE: invention refers to medicine, dentistry, oncology and radiology, and may be used for improving the quality of dental aid to the patients suffering malignancies in head and neck after radiation therapy. Reduction of the mechanical properties of dental dentine radiated in therapeutic doses in vitro is stated in a maxillofacial phantom representing a tissue-equivalent heterogenous antropomorphic human oral phantom with cells to place extracted teeth of an individual. Tissue substitutes for creating the phantom are presented by porcine bones and mixed imitated soft tissue, weight portions: paraffin - 100, magnesium oxide (MgO) - 29.06, calcium carbonate - 0.94. The dose control is ensured by light-sensitive film and thermoluminescent dosimetry.
EFFECT: method provides evaluation of a degree of radiation damages of dental dentine, higher accuracy of dose correlation in therapeutic maxillofacial tumour radiation with changing the mechanical properties of the dentine and its strength.
5 dwg, 2 tbl
SUBSTANCE: group of invention refers to medicine, medical equipment, urology, radiation therapy in oncology. Penile brachytherapy is ensured by an individual applicator by simulating a profile of its internal surface. The method involves individual radiation-monitoring planning, selection of a radiation target, placement of the organ inside the applicator and a session of radiation therapy by radiation sources placed in endostate channels. The individual applicator is made of a biocompatible material, comprises receiving channels for endostates able to move and enclose the radiation sources, two working half-cylinders made of an elastic silicone compound and a double fixing platform. The shape of the internal surface of the half-cylinders is matched with the penis surface profile and provided with a balanus retainer in the form of a circular flange at the level of a coronary groove. The half-cylinder thickness is 8-13 mm, the body comprises the twelve equispaced parallel channels for endostates of the internal diameter 2.0 mm. The double fixing platform represents two equal-sized rings; its upper part comprises a cylinder coupling the working half-cylinders of the internal diameter equal to the external diameter of the working half-cylinders with equal heights; and two holes coinciding with guide bushings of a lower part of the platform. Both parts of the platform are provided with coinciding fixing holes.
EFFECT: inventions provide the application radiation therapy in the irregular surface profile, immediate delivery of the radiation source to the tumour without damaging the surrounding tissues, reproducibility of the sessions in any brachytherapeutic apparatus with wireline supply of the radiation source, homogenous graduated distribution in the target, minimised dose for urethra, reduced frequency and intensity of radioreactions.
4 cl, 3 dwg, 1 ex
SUBSTANCE: invention refers to medicine, oncology, and may be used for treating squamous cell cancer of anal canal. The therapy is two-staged. The first stage involves radiation teletherapy in a dynamic dose fractionation mode with the paratumoural introduction of chemopreparations. The remote teletherapy is preceded by anaesthesia from 2 sides in a lateral direction from rectal walls at the distance of 3-4 cm at conditional 9 and 3 o'clock and at the depth of 8-10 cm behind M. Levatoris ani. As chemopreparations, 5-fluorouracil and methotrexate are administered sequentially via the same injection canals in standard calculated doses 4 times every second day. Thereafter 2-3 days later, it is followed by the remote teletherapy according to the dynamic dose fractionation schedule. Before the radiation, the similar anaesthesia is provided in enlarged fractions, and metronidazole is administered paratumourally at 2-3 mg/cm3 of the tumour. The second stage follows after a 2-week pause and involves endoluminal brachytherapy.
EFFECT: implementing the method enables higher clinical effectiveness and reduced toxic load on the patient's body ensured by the targeted administration of the preparation and possibility to achieve a high concentration in a loci-regional system of the tumour.
SUBSTANCE: invention refers to medicine, oncology. It involves 3-5 sessions of argon-plasma recanalisation of a tumour stenosis area at power 60-70 Wt, duration of each application max. 5 sec, argon supply rate 2.0-2.2 l/min, every 3-5 days. It is followed by 3 sessions of endoluminal brachytherapy of single radiation dose 7 Gy, once a week, total radiation dose 21 Gy. An endostate is placed so that to enable the source moving at the distance covering the tumour and the oesophageal wall above and below the tumour by 2-3 cm. It is combined with 2 cycles of chemotherapy according to the schedule: cisplatin 75 mg/m intravenously on the 1st day, 5- fluorouracil 1000 mg/m2 daily, continuous intravenous infusion on the 1st-5th days. The first session of brachytherapy is combined with the beginning of chemotherapy. The next course of polychemotherapy follows in 28 days. A tumour regression degree is estimated to consider a possibility of the surgical management to the extent of sub-total esophagectomy accompanied by three-zone lymphodissection and single-step repair with a wide gastric graft.
EFFECT: method enables higher resectability and radicality of the surgical management ensured by downsizing the initial tumour.
SUBSTANCE: invention refers to medicine, namely oncology and radiology, and may be used for treating stage IIA Hodgkin's lymphoma. That is ensured by 3-4 therapeutic courses of chemotherapy by the scheme ABVD - adriablastine, bleomycine, vinblastine, dacarbazine. It is followed by chemotherapy by the scheme AVB - adriablastine, vinblastine, dacarbazine. From the 2nd day of the AVD course, the radiation therapy covering initially involved zones is applied at single basic dose 1.2 Gy, daily 2 times a day every 4 hours. If the initial tumour lesion is less than 5 cm, the radiation therapy is applied to total basic dose 30 Gy, while the lesions more than 5 cm requiring dose up to 36 Gy.
EFFECT: method provides reducing total treatment length at least by 2 months, reducing a risk of recurrences, reducing a probability of secondary tumours and late complications of the radiation therapy ensured by the intensified combined chemoradiation treatment.
SUBSTANCE: invention relates to medicine, oncology and radiology and consists in carrying out complex treatment by installation of endobronchial reverse valve into bleeding bronchus. At this background performed is external beam radiotherapy (EBRT) TFD 40 Gy, with radiomodifier: 5 fluorouracil - 250 mg, course dose - 4-5 g, or cysplatin - 10 mg, course dose - 120 mg, which are introduced daily, intravenously 30 minutes before the beginning of EBRT session. 14 days after completion of the first stage of EBRT fibrobronchoscopy (FBS) is performed with removal of bronchoblocker, and the second stage of EBRT TFD 30 Gy is performed to total dose for two stages EBRT TFD 70 Gy, with application of the same radiomodifiers in the same mode. 30 days after finishing EBRT FBS is made and is tumour remains in bronchus lumen or there is a suspicion of it, photodynamic preparation is introduced intravenously, and after 4 hours FBS and laser irradiation of tumour are carried out. Control examination of tracheobroncial tree is carried out after 30 days and after 26 months.
EFFECT: method ensures increase of life expectancy and improvement of its quality for patients with non-operable lung cancer complicated by hemorrhage.
SUBSTANCE: invention refers to medicine, concerns treating cancer. The tumour is exposed to gamma photon with a radiation source cobalt-60 at gamma photon radiation energy 1.25 MeV. A patient takes herbal infusion 400-500 ml 30-40 min before the radiation therapy session: Alexandrian laurel leaves, burdock leaves, alder blossom, dill seeds, celandine herb, nettle herb and sage herb in equal portions. The plants are pre-dried in the shade to humidity 14-16 %, then each is taken in the amount of 100 g, mixed and powdered. The herbal powder 40-50 g is filled with boiling water 500-600 ml, boiled for 3 min, and settled for 2-3 hours. Between the radiation therapy sessions, the patient takes the infusion 200-250 ml twice a day, and after the termination of the therapeutic course, the infusion 200-250 ml is prescribed once a day.
EFFECT: method provides clinical effectiveness ensured by prevented metastases formation.
SUBSTANCE: invention refers to medicine, namely oncology, and can be used for treating cervical cancer. That is ensured by radiation teletherapy and brachytherapy. Each brachytherapy session is preceded by bringing the Hydrogel Coletex-M Tissue 3-5 ml to the tumour before 12-18 hours. Before gel contact, the Coletex-M Tissue is introduced. Further,1-1,5 hours prior to the brachytherapy session, the textile tissue is removed, and Hydrogel Coletex-ADL Tissue 4-6 ml is brought to the tumour. Preliminary, the Hydrogel Coletex-ADL Tissue is added with lidocaine to achieve the gel concentration 4-6%.
EFFECT: method provides reduced total toxicity and drug load ensured by the required concentration of metronidazole maintained in the tumour before the radiation session, and also analgesia without using narcotic preparations, optimised time and geometry of centring introduction that allows intensifying the damage exposure on the tumour.